BCR-ABL kinase is dead; long live the CML stem cell.

@article{Perl2011BCRABLKI,
  title={BCR-ABL kinase is dead; long live the CML stem cell.},
  author={Alexander Perl and Martin Carroll},
  journal={The Journal of clinical investigation},
  year={2011},
  volume={121 1},
  pages={22-5}
}
Chronic myeloid leukemia (CML) is a hematopoietic disease characterized by expansion of myeloid blood cells. It is caused by the t(9;22) chromosomal translocation that results in the expression of the fusion tyrosine kinase BCR-ABL. Tyrosine kinase inhibitor (TKI) therapy has led to long-term remissions, but patients remain BCR-ABL+. There is agreement that TKIs do not kill CML stem cells; however, it is controversial whether this is because of a lack of BCR-ABL kinase inhibition in CML stem… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…